Surface Oncology Inc (OQ:SURF)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 50 Hampshire St Fl 8
CAMBRIDGE MA 02139-1548
Tel: N/A
IR: See website
Key People
Daniel S. Lynch
Executive Chairman of the Board
J. Jeffrey Goater
President, Chief Executive Officer, Director
Jessica Fees
Principal Financial Officer, Principal Accounting Officer, Senior Vice President, Finance and Treasurer
Vito J. Palombella
Chief Scientific Officer
Wendy Dwyer
Chief Business Officer
Robert W. Ross
Chief Medical Officer
Liisa I. Nogelo
Chief Legal Officer, Secretary
Business Overview
Surface Oncology, Inc. is a clinical-stage immuno-oncology company. The Company is engaged in the development of cancer immunotherapies. To unlock the potential of cancer immunotherapy, the Company is targeting a set of immune processes by which cancer cells evade immune recognition and attack. Its programs are built upon insights about how to improve the immune system's recognition and elimination of cancer cells. These include approaches to improve the effectiveness of antigen presentation to the adaptive immune system, to block the activity of a range of suppressor cells in the tumor microenvironment, and to counter the immunosuppressive environment that selectively accumulates in and around the tumor. By targeting the interface of innate and adaptive immunity, it hopes to expand the reach of cancer immunotherapy to patients in need of treatment.
Financial Overview
For the six months ended 30 June 2020, SurfaceOncology Inc revenues increased from $14.6M to $38.6M. Netincome totaled $7.8M vs. loss of $22M. Revenues reflect anincrease in demand for the Company's products and servicesdue to favorable market conditions. Net Income reflectsResearch and development - Balancing decrease of 27% to$18.2M (expense), General and administrative - Balancingdecrease of 34% to $5.4M (expense).
Employees: 49 as of Mar 10, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $227.37M as of Sep 30, 2020
Annual revenue (TTM): $39.03M as of Sep 30, 2020
EBITDA (TTM): -$21.00M as of Sep 30, 2020
Net annual income (TTM): -$23.97M as of Sep 30, 2020
Free cash flow (TTM): -$55.80M as of Sep 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 40,676,849 as of Nov 5, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.